We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Free PSA for Detecting Prostate Cancer

Donald R. Peven, MD
JAMA. 1998;280(21):1825. doi:10-1001/pubs.JAMA-ISSN-0098-7484-280-21-jbk1202.
Text Size: A A A
Published online


To the Editor.—The article by Dr Catalona and colleagues1 claims that the free PSA assay can reduce the number of biopsies performed in men with normal DRE findings and total PSA levels between 4.0 and 10.0 ng/mL, while missing only a minimal number of patients with prostate cancer. However, a critical examination of their data shows that the test has significant weaknesses and in fact is almost worthless.

Quantitative evaluation of the data reveals how many patients would be missed by a test that is 95% sensitive. The article by Catalona et al shows that the initial screen (normal DRE findings, total PSA of 4.0-10.0 ng/mL) identifies a population of men with a 25% prevalence of prostate carcinoma. Therefore, a hypothetical group of 400 such men would include 100 men with prostate carcinoma and 300 disease-free men. The free PSA test, used at a cutoff of 25% as recommended by the article, has a sensitivity of 95% and a specificity of 20%. At 95% sensitivity, the test would correctly identify 95 of the 100 patients with cancer, missing 5 of them. At 20% specificity, only 60 of the 300 unaffected patients would be classified as not needing biopsies (Table 1).


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.